The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Stacey Ku - TD Cowen - Analyst
: So before we drill down into specific questions, do you want to just very briefly provide an overview of the recent earnings update for '24 and
maybe again very briefly the view and outlook for '25?
Question: Stacey Ku - TD Cowen - Analyst
: Okay, well, wonderful. So just given the recent kind of pipeline news, I think we'll start there, update on SPN-820 Phase 2b study for TRD. So ahead
of the update, we had gotten a lot of inbound and so our sense for that investors are really optimistic. Do you want to just talk about some of the
kind of post data analysis, what you're kind of looking at with Navitor and kind of [start from there]?
Question: Stacey Ku - TD Cowen - Analyst
: Okay. And you talked about the different subset of patients, specifically you looked at kind of the MDD patients in the study and the TRD patients
in the study and saw no --?
Question: Stacey Ku - TD Cowen - Analyst
: Okay. And timing of strategic conclusions are going to happen this year?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 03, 2025 / 4:10PM, SUPN.OQ - Supernus Pharmaceuticals Inc at TD Cowen Healthcare Conference
Question: Stacey Ku - TD Cowen - Analyst
: The timing of kind of strategic conclusions around 820?
Question: Stacey Ku - TD Cowen - Analyst
: Understood. You've also in the last year or so released proof-of-concept results for 817, so SPN-817 in treatment resistant seizures. I just want to
talk about your development plans there, recent kind of efficacy results we've seen, and obviously the opportunity in [focal and epilepsy].
Question: Stacey Ku - TD Cowen - Analyst
: Okay. And by the way, for the Phase 2b, you do believe you said you've extended the titration period? Is that correct from your concept?
Question: Stacey Ku - TD Cowen - Analyst
: ESCAPE Bioscience obviously (inaudible) has had success despite a tough titration period and kind of tolerability.
Question: Stacey Ku - TD Cowen - Analyst
: Last question on 817 then. Could we get an update at least just on tolerability this year from the open-label extension trial? Any comments as we
move through to the Phase 2b?
Question: Stacey Ku - TD Cowen - Analyst
: Okay. You discussed that you exited Q4 with around $400 million, and you did kind of mention business development potential. How much time
are you spending there these days? Maybe talk about what stage of development you might think about, how big you go, are you comfortable
leveraging up?
Question: Stacey Ku - TD Cowen - Analyst
: Understood. You mentioned ONAPGO launch. Do you want to talk about launch timing? What else needs to be done to be ready and maybe the
infrastructure that's required and what's already set up?
Question: Stacey Ku - TD Cowen - Analyst
: So what are your maybe your expectations for this year for ONAPGO and then maybe remind us the peak sales opportunity here?
Question: Stacey Ku - TD Cowen - Analyst
: Okay. But we'll have to think about pricing and payer reimbursement and kind of clinician need. Okay, understood. Obviously, Calgary is key to
Supernus for the next few years. The pediatric launch continues to kind of chug along in our view, but how is the adult launch progress progressing
for you all? What else needs to be done to increase adoption? Maybe remind us the recent study results for Qelbree and ADHD with depression
comorbidities and the adult awareness campaign.
Question: Stacey Ku - TD Cowen - Analyst
: Okay, understood. So it sounds like on the last earnings call, we talked about Qelbree consensus for 2025, around $280 million. Seems to be within
a general range of something that you're comfortable with. I see you nodding.
But let's look long term, how big do you think it could become? Obviously, 100 million prescriptions, big, big market, [non-stimulants], some smaller
piece of the pie. So how do you think about how Qelbree could grow?
Question: Stacey Ku - TD Cowen - Analyst
: In the last few moments, maybe remind us Qelbree durability, how are you guiding investors on [activity]?
Question: Stacey Ku - TD Cowen - Analyst
: Any other questions? Oh, wonderful. Thank you so much for the time.
| 
